Special Report: Ahead of near-term readouts from a trial investigating NUZ-001’s effect in a mouse model of Parkinson’s, ...

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective candidate, NUZ-001, using Tessara Therapeutics' 3D human brain model. The ...

Neurizon Therapeutics (ASX: NUZ) has reported positive results from an independent study into the effects of neuroprotective ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Neurizon Therapeutics Ltd (ASX:NUZ) has yielded positive results from an independent study – conducted in collaboration with ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

"All the indications have high unmet need and large markets," Jain said. Neurizon Therapeutics (ASX:NUZ) is targeting amyotrophic lateral sclerosis (ALS), the most common form of motor neurone ...

Neurizon Therapeutics continues to make strides on its NUZ-001 treatment for ALS, paving the way for next stage clinical trials. In this episode, Tylah Tully gives the skinny on Neurizon ...

Neurizon Therapeutics (ASX:NUZ) announced positive respiratory function data for its ALS treatment candidate, NUZ-001, as it prepares for entry into the HEALEY ALS platform trial in the second half of ...